SLC5A2 and type 2 diabetes mellitus: By decreasing fasting plasma glucose levels and stimulating insulin sensitivity in diabetic patients, thus having the potential to combat T2DM in ways similar to the pharmaceutical intervention of SGLT2 inhibitors in helping to reabsorption glucose from the kidneys, these agents offer great potential in this field.